Navigation Links
Icahn School of Medicine at Mount Sinai awarded $2.7 million from NIH to investigate novel therapy for eczema
Date:11/25/2013

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema. Currently, no treatments are available that achieve long-term remission without difficult side effects for this debilitating skin disorder, characterized by inflammation, severe itching, and a rash that can adversely affect many aspects of everyday life.

The team will investigate the efficacy of a new intravenous medication, ILV-094, which blocks IL-22, an important protein that has been shown in animal models to trigger epidermal growth and differentiation abnormalities and chronic inflammation, which are major features of AD. The researchers see the study as potentially groundbreaking in using "narrow pathway"-targeted immune interventions for not just AD, but other "allergic" inflammatory diseases of the skin or other organs, such as asthma.

At the Icahn School of Medicine at Mount Sinai, Emma Guttman, MD, PhD, Associate Professor of Dermatology, and Director of the Laboratory for Inflammatory Skin Diseases, and Mark Lebwohl, MD, Professor and Chair of Dermatology, will lead the study. James G. Krueger, MD, PhD, D. Martin Carter Professor and head of the Laboratory for Investigative Dermatology at The Rockefeller University, will oversee the mechanistic studies for the trial. Dr. Guttman has a joint appointment at Rockefeller and will conduct clinical and mechanistic studies at both institutions.

Dr. Guttman was the first investigator to show in humans that a separate population of T cells secrete interleukin 22 (IL-22) and she also discovered the importance of the Th22 pathway and IL-22 in AD.

"Dr. Guttman has been at the forefront of many of the most important strides in understanding the pathophysiology of atopic dermatitis," said Dr. Lebwohl. "This trial is an important step in developing safer treatments for patients with moderate to severe AD."

"I hope that this research results in a final proof of concept and a novel treatment for AD without side effects," said Dr. Guttman. The clinical trial is expected to last five years. The majority of the clinical trial, will be conducted at the Icahn School of Medicine at Mount Sinai.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Icahn School of Medicine at Mount Sinai Honors Innovators in Scientific Research and Health Care Philanthropy at 2013 Commencement Ceremony
2. Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh to Collaborate on Clinical Studies for Mucopolysaccaridoses
3. Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration
4. Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
5. World-Renowned Gastroenterologist Jean-Frédéric Colombel, MD, Joins the Icahn School of Medicine at Mount Sinai
6. Janina A. Longtine, MD of the Icahn School of Medicine at Mount Sinai Elected President of the Association for Molecular Pathology
7. A Best Manuscript Award Goes to the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai
8. A Best Manuscript Award goes to Icahn School of Medicine at Mount Sinai
9. Four Researchers from Icahn School of Medicine at Mount Sinai Among the 400 Most Highly Influential Biomedical Researchers in the World
10. Even Preschoolers View the Overweight Negatively
11. Catastrophic Head Injuries to High School Football Players Rising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
(Date:6/23/2016)...  The National Pharmaceutical Council (NPC) today announced ... research organization as its newest member.  ... president and chief scientific officer, Mallinckrodt Pharmaceuticals, will ... Board of Directors. ... us in support of our efforts to conduct ...
Breaking Medicine Technology: